SEARCH

SEARCH BY CITATION

References

  • 1
    Primary Liver Disease of Liver Transplant Recipients 1991 and 1992 (From the UNOS Scientific Registry). UNOS Update 1993;9(8):27.
  • 2
    Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317322.
  • 3
    Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, et al. Treatment of post transplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 2002;8:623629.
  • 4
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673684.
  • 5
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958965.
  • 6
    Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999;31:11131114.
  • 7
    Neyts J, Meerbach A, McKenna P, DeClercq E. Use of yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996;30:125132.
  • 8
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002;8:4046.
  • 9
    Paterson DL, Singh N, Panebianco A, Wannstedt CF, Wagener MM, Gayowski T, Marino IR. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998;66:593598.
  • 10
    Weisner RH, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442450.
  • 11
    Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362369.
  • 12
    Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999;30:12931298.
  • 13
    Platz KP, Mueller AR, Willimski B, Mansoorian, Berg T, Neuhaus R, et al. Indications for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transpl Proc 1998;30:14681469.
  • 14
    Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000;69:991994.
  • 15
    Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil. Clin Transplant 1996;10:7784.
  • 16
    Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990;12:11321146.
  • 17
    Crumpacker CS. Overview of ribavirin treatment of infection caused by RNA viruses. In: RASmith, VKnight, and SmithJAD, (eds). Clinical Applications of Ribavirin. Orlando: Academic Press, 1984: 3338.
  • 18
    Wright T, Shiffman ML, Knox S, Ette E, Kauffman RS, Alam J. Dose-ranging study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C (abstract). Hepatology 1999;30:408A.
  • 19
    Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473477.
  • 20
    Platz KP, Mueller AR, Berg T, Neuhaus R, Hopf U, Loback H, Neuhaus P. Searching for the optimal management of hepatitis C patients after liver transplantation. Transpl Int 1998;11(suppl 1):S209211.
  • 21
    Afdhal N, Flamm S, Imperial JC, Malet PF, Tong M, Herrine SK, et al. Analyses of 40 KDA Peginterferon alfa-2A (Pegasys) in combination with ribavirin, mycophenolate mofetil, amantidine, or amantidine plus ribavirin in patients that relapsed or did not respond to rebetron therapy: A report of two randomized, multicenter, efficacy and safety studies. Hepatology 2001;34:A277.